133 related articles for article (PubMed ID: 17909257)
21. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1.
Cesarone G; Edupuganti OP; Chen CP; Wickstrom E
Bioconjug Chem; 2007; 18(6):1831-40. PubMed ID: 17922544
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status.
Jares P; Rey MJ; Fernández PL; Campo E; Nadal A; Muñoz M; Mallofré C; Muntané J; Nayach I; Estapé J; Cardesa A
J Pathol; 1997 Jun; 182(2):160-6. PubMed ID: 9274525
[TBL] [Abstract][Full Text] [Related]
23. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA.
Paudyal B; Zhang K; Chen CP; Wampole ME; Mehta N; Mitchell EP; Gray BD; Mattis JA; Pak KY; Thakur ML; Wickstrom E
Nucl Med Biol; 2013 Nov; 40(8):994-9. PubMed ID: 24074944
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Deng H; Wang H; Wang M; Li Z; Wu Z
Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
[TBL] [Abstract][Full Text] [Related]
25. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
Li F; Jiang S; Zu Y; Lee DY; Li Z
J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
[TBL] [Abstract][Full Text] [Related]
26. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.
Parry JJ; Andrews R; Rogers BE
Breast Cancer Res Treat; 2007 Jan; 101(2):175-83. PubMed ID: 16838112
[TBL] [Abstract][Full Text] [Related]
27. MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acids.
Sun X; Fang H; Li X; Rossin R; Welch MJ; Taylor JS
Bioconjug Chem; 2005; 16(2):294-305. PubMed ID: 15769082
[TBL] [Abstract][Full Text] [Related]
28. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.
Wei L; Butcher C; Miao Y; Gallazzi F; Quinn TP; Welch MJ; Lewis JS
J Nucl Med; 2007 Jan; 48(1):64-72. PubMed ID: 17204700
[TBL] [Abstract][Full Text] [Related]
30. Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates.
Jia F; Figueroa SD; Gallazzi F; Balaji BS; Hannink M; Lever SZ; Hoffman TJ; Lewis MR
J Nucl Med; 2008 Mar; 49(3):430-8. PubMed ID: 18287262
[TBL] [Abstract][Full Text] [Related]
31. VPAC1 receptors for imaging breast cancer: a feasibility study.
Thakur ML; Zhang K; Berger A; Cavanaugh B; Kim S; Channappa C; Frangos AJ; Wickstrom E; Intenzo CM
J Nucl Med; 2013 Jul; 54(7):1019-25. PubMed ID: 23651947
[TBL] [Abstract][Full Text] [Related]
32. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
33. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
34. Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products.
Thakur ML; Devadhas D; Zhang K; Pestell RG; Wang C; McCue P; Wickstrom E
J Nucl Med; 2010 Jan; 51(1):106-11. PubMed ID: 20008985
[TBL] [Abstract][Full Text] [Related]
35. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
37. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2.
Peng F; Lu X; Janisse J; Muzik O; Shields AF
J Nucl Med; 2006 Oct; 47(10):1649-52. PubMed ID: 17015901
[TBL] [Abstract][Full Text] [Related]
38. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake.
Basu S; Wickstrom E
Bioconjug Chem; 1997; 8(4):481-8. PubMed ID: 9258444
[TBL] [Abstract][Full Text] [Related]
40. Fluorescence Imaging of Huntingtin mRNA Knockdown.
Oh E; Liu Y; Sonar MV; Merry DE; Wickstrom E
Bioconjug Chem; 2018 Apr; 29(4):1276-1282. PubMed ID: 29451775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
